12/18
09:48 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
12/18
08:27 am
coya
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) [Yahoo! Finance]
Medium
Report
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) [Yahoo! Finance]
12/18
08:15 am
coya
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
Medium
Report
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
12/4
07:33 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $15.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $15.00 price target on the stock.
11/25
08:15 am
coya
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
Neutral
Report
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
11/19
08:15 am
coya
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Low
Report
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
11/11
08:09 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
11/7
09:51 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Low
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
11/6
08:00 am
coya
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
Medium
Report
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
11/1
08:18 am
coya
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer [Yahoo! Finance]
Medium
Report
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer [Yahoo! Finance]
11/1
08:15 am
coya
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
Medium
Report
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
10/30
09:25 am
coya
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Medium
Report
Coya Therapeutics, Inc. (NASDAQ: COYA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
10/29
06:30 am
coya
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
High
Report
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
10/28
08:00 am
coya
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
High
Report
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
10/23
04:05 pm
coya
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
Low
Report
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
10/22
09:11 am
coya
Coya Therapeutics looks to raise $10M in private placement [Seeking Alpha]
High
Report
Coya Therapeutics looks to raise $10M in private placement [Seeking Alpha]
10/22
09:00 am
coya
Coya Therapeutics Announces $10.0 Million Private Placement
High
Report
Coya Therapeutics Announces $10.0 Million Private Placement
10/8
09:15 am
coya
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
Low
Report
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100